TTC29

Across TCGA pan-cancer cohorts, TTC29 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated TTC29 data layer compared with 17 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher TTC29 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TTC29 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

OV, STAD, and DLBC are the cancer types where TTC29 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.007	0.844	<.001	48	view →
STAD	OS	Median	III,IV	0.075	0.633	<.001	30	view →
DLBC	OS	Median	All	0.053	0.936	<.001	12	view →
SCLC	DFS	Median	All	0.228	0.578	.020	9	view →
UCEC	DFS	Median	II,III,IV	0.855	0.306	.044	8	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LIHC	DFS	Median	All	0.043	0.527	<.001	6	view →
SKCM	OS	Median	IV	0.415	0.861	.014	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

TTC29–OV (OS)

Open the OV breakdown →